NASDAQ:SLDB - Solid Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.13
  • Forecasted Upside: -11.05 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.01
▼ -1.2 (-13.03%)
1 month | 3 months | 12 months
Get New Solid Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLDB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLDB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.13
▼ -11.05% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $7.13, with a high forecast of $12.50 and a low forecast of $3.00. The average price target represents a -11.05% upside from the last price of $8.01.
Buy
The current consensus among 4 polled investment analysts is to buy stock in Solid Biosciences. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2021Chardan CapitalReiterated RatingBuy$12.50High
i
Rating by Gbola Amusa at Chardan Capital
1/8/2021Credit Suisse GroupUpgradeUnderperform ➝ Neutral$2.00 ➝ $7.00High
i
10/1/2020Chardan CapitalBoost Price TargetBuy$5.00 ➝ $12.50High
i
Rating by Gbola Amusa at Chardan Capital
8/14/2020Chardan CapitalReiterated RatingBuy$5.00Medium
i
Rating by Gbola Amusa at Chardan Capital
7/27/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$3.00High
i
Rating by Joseph Schwartz at SVB Leerink LLC
5/21/2020NomuraReiterated RatingBuy$6.00Low
i
5/9/2020Chardan CapitalReiterated RatingBuy$5.00High
i
Rating by Gbola Amusa at Chardan Capital
5/8/2020NomuraLower Price TargetBuy$10.00 ➝ $6.00Low
i
3/23/2020Chardan CapitalReiterated RatingBuy$6.75 ➝ $5.00High
i
12/18/2019Nomura SecuritiesBoost Price TargetBuy$6.00 ➝ $10.00High
i
11/12/2019Credit Suisse GroupLower Price TargetUnderperform ➝ Hold$6.00 ➝ $2.00High
i
10/11/2019Evercore ISIInitiated CoverageOutperform$22.00High
i
8/29/2019CitigroupDowngradeNeutral ➝ Sell$6.00High
i
Rating by Joel Beatty at Citigroup Inc.
8/19/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$8.00 ➝ $15.00High
i
Rating by J. Schwartz at SVB Leerink LLC
8/16/2019Chardan CapitalUpgradeNeutral ➝ Buy$7.50 ➝ $10.00High
i
Rating by G. Amusa at Chardan Capital
5/16/2019CitigroupSet Price TargetHold$6.00Low
i
Rating by Joel Beatty at Citigroup Inc.
5/14/2019Chardan CapitalDowngradeBuy ➝ Neutral$15.00 ➝ $7.50High
i
Rating by G. Amusa at Chardan Capital
5/14/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$5.00 ➝ $4.00High
i
5/14/2019Credit Suisse GroupDowngradeNeutral ➝ Underperform$7.00 ➝ $6.00High
i
2/8/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by J. Schwartz at SVB Leerink LLC
2/8/2019CitigroupUpgradeSell ➝ Neutral$8.00Medium
i
2/7/2019Chardan CapitalReiterated RatingBuy$15.00High
i
12/10/2018BTIG ResearchInitiated CoverageNeutralLow
i
12/3/2018CitigroupBoost Price TargetHold ➝ Sell$25.00 ➝ $31.00High
i
11/6/2018CitigroupInitiated CoverageSell$25.00High
i
9/6/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$38.00High
i
6/25/2018Nomura SecuritiesBoost Price TargetBuy$37.00 ➝ $57.00High
i
6/24/2018Chardan CapitalReiterated RatingBuy$60.00Low
i
Rating by G. Amusa at Chardan Capital
6/20/2018SVB LeerinkBoost Price TargetOutperform$28.00 ➝ $50.00High
i
Rating by J. Schwartz at SVB Leerink LLC
5/10/2018Chardan CapitalReiterated RatingBuy$37.50Low
i
Rating by G. Amusa at Chardan Capital
5/10/2018SVB LeerinkBoost Price TargetOutperform$14.00 ➝ $28.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
4/2/2018SVB LeerinkLower Price TargetOutperform ➝ Hold$36.00 ➝ $14.00Medium
i
Rating by J. Schwartz at SVB Leerink LLC
3/19/2018Nomura SecuritiesLower Price TargetBuy ➝ Buy$52.00 ➝ $37.00Low
i
3/15/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$28.00High
i
2/21/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$40.00High
i
Rating by G. Amusa at Chardan Capital
2/20/2018Nomura SecuritiesInitiated CoverageBuy ➝ Buy$52.00Medium
i
2/20/2018Nomura InstinetInitiated CoverageBuy$52.00High
i
2/20/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$36.00High
i
Rating by J. Schwartz at SVB Leerink LLC
2/20/2018JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$28.00High
i
2/20/2018The Goldman Sachs GroupInitiated CoverageNeutral$31.00High
i
(Data available from 2/26/2016 forward)
Solid Biosciences logo
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $8.01
$7.75
$9.74

50 Day Range

MA: $7.08
$6.04
$9.74

52 Week Range

Now: $8.01
$1.93
$11.58

Volume

1,653,861 shs

Average Volume

1,280,503 shs

Market Capitalization

$484.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Solid Biosciences?

The following sell-side analysts have issued research reports on Solid Biosciences in the last twelve months: Chardan Capital, Credit Suisse Group AG, Nomura, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for SLDB.

What is the current price target for Solid Biosciences?

4 Wall Street analysts have set twelve-month price targets for Solid Biosciences in the last year. Their average twelve-month price target is $7.13, suggesting a possible downside of 15.2%. Chardan Capital has the highest price target set, predicting SLDB will reach $12.50 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $3.00 for Solid Biosciences in the next year.
View the latest price targets for SLDB.

What is the current consensus analyst rating for Solid Biosciences?

Solid Biosciences currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLDB will outperform the market and that investors should add to their positions of Solid Biosciences.
View the latest ratings for SLDB.

What other companies compete with Solid Biosciences?

How do I contact Solid Biosciences' investor relations team?

Solid Biosciences' physical mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company's listed phone number is 617-337-4680. The official website for Solid Biosciences is www.solidbio.com.